ACE D/I Polymorphism and Incidence of Post-PTCA Restenosis
- 1 March 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hypertension
- Vol. 37 (3) , 851-855
- https://doi.org/10.1161/01.hyp.37.3.851
Abstract
Early restenosis is the major complication of percutaneous transluminal coronary angioplasty (PTCA), occurring in ≈30% of all initially successful procedures. The D/I polymorphism of the ACE gene, which has variably been reported to represent a risk factor for manifestations of ischemic heart disease, has recently been implicated in the pathophysiology of restenosis after PTCA by some investigators but not by others. All studies conducted thus far involved relatively small sample sizes. We investigated the possible association of ACE D/I genotype and post-PTCA restenosis in a large, prospective sample of patients followed by quantitative coronary angiography. The ACE D/I gene polymorphism was characterized in a cohort of 779 patients, of whom 342 (cases) had developed restenosis (as defined by >50% loss of lumen compared with immediate postprocedure results) at repeat quantitative coronary angiography at 6 months after PTCA. Allele frequencies for the ACE D and I alleles were 0.58 and 0.42 in cases and 0.58 and 0.42 in control subjects. All observed genotype frequencies were in Hardy-Weinberg equilibrium. There was no evidence for an association between genotype and restenosis or degree of lumen loss. The data from this largest study of its kind conducted so far provide no evidence for an association of the ACE D/I allelic polymorphism with incidence of restenosis after PTCA. On the basis of the power of this study, we conclude that in a general population, the ACE D/I polymorphism is not a useful marker to assess risk of post-PTCA restenosis.Keywords
This publication has 10 references indexed in Scilit:
- The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal riskJournal Of Hypertension, 1997
- The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventionsAtherosclerosis, 1997
- ACE Polymorphism, a Genetic Predictor of Occlusion After Coronary AngioplastyThe American Journal of Cardiology, 1996
- Angiotensin-converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectorisThe American Journal of Cardiology, 1996
- Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplastyThe Lancet, 1995
- Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazaprilJournal of the American College of Cardiology, 1995
- Early angiographic changes of side branches arising from a Palmaz-Sehatz stented coronary segment: Results and clinical implicationsJournal of the American College of Cardiology, 1994
- A potent genetic risk factor for restenosisNature Genetics, 1993
- Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular InjuryScience, 1989
- Re-Stenosis after Successful Coronary AngioplastyNew England Journal of Medicine, 1988